DJ Nexstim OYJ (NXTMH-FI): Reverse stock split to improve trading conditions
Dow Jones received a payment from EQS/DGAP to publish this press release.
goetzpartners securities Limited
Nexstim OYJ (NXTMH-FI): Reverse stock split to improve trading conditions
28-Nov-2018 / 13:09 GMT/BST
*Free to access research and investor meetings in a post-MiFID2 world.*
*This research report is intended for use only by persons who qualify as
professional investors or eligible counterparties (institutional investors) in
the applicable jurisdiction, and not by any private individuals or other
persons who qualify as retail clients.*
*Published to the market and investors on 28th November 2018 @ 10.39am (London
time).*
*Nexstim OYJ (NXTMH-FI): Reverse stock split to improve trading conditions*
*Recommendation: OUTPERFORM*
*Target Price: EUR8.40 (from EUR0.28)*
*Current Price: EUR1.24 (CoB on 27th November 2018) *
*KEY TAKEAWAY*
Nexstim announced the completion of a reverse stock split at a ratio of 1:30
in order to improve trading conditions. We therefore adjust our target price
in line with the share consolidation and continue to believe that the shares
represent an asymmetric risk profile considering current trading levels. In
our view, the diagnostics segment represents a solid valuation floor with
limited downside risk and potential for market expansion. The recent signing
of the distribution agreement with Ampere Medical Limited in Hong Kong and the
fact that both product lines are well-differentiated from the competition
leaves limited commercial execution risk and minimal regulatory risk. Hence,
we reiterate and maintain our OUTPERFORM recommendation and adjust our target
price on a purely technical basis to EUR8.40 (from EUR0.28) to reflect the
share consolidation.
*1:30 reverse stock split to improve trading conditions*
Nexstim announced the completion of the reduction of the quantity of its
shares resolved at the Extraordinary General Meeting on 21st November 2018.
The share consolidation was carried out so that each 30 shares of the company
prior to completion of the reverse stock split corresponds to one new share.
42,721 new shares were issued in order to make the number of shares held by
individual investors divisible by 30, bringing the total number of outstanding
shares in the market to 3,261,475 following the annulment (including the
issuance of 9,000 new shares to the company). We highlight to investors that
this is solely a technical adjustment with the purpose of making the shares
more marketable, however, this could have minor effects on liquidity as the
number of shares in the open market decreases. As a result of the adjustment,
the price of each share increased proportionally from EUR0.05 (CoB 23rd Nov)
to EUR1.58 (as at market opening 26th Nov).
*First NBT system for applications in depression already installed in Hong
Kong*
Nexstim recently announced the signing of a distribution agreement with Ampere
Medical Limited, a Hong Kong-based specialist neuromodulation distributor,
thus opening avenues for Nexstim to tap into a market of over 200,000 patients
suffering from depression in Hong Kong. Ampere Medical Limited has already
received its first order from a TMS Centre under the Smile and Face Medical
Group in Hong Kong, which validates both Nexstim's technology as well as the
distribution agreement and could pave the way for further deals providing
access to the Mainland China market.
*Development of wireless EMG devices funded by Business Finland*
Nexstim recently secured EUR342k of R&D loans from Business Finland, a public
funding agency for research funding in Finland. The development project is
part of ELASTRONICS, Finland's largest research project for the development of
wireless Electromyography ("EMG") devices. Nexstim uses EMG to measure muscle
responses in patients in order to determine the intensity of therapy and to
establish input intensity in patients undergoing functional brain mapping
before neurosurgery. A wireless system would provide an easier and more
comfortable alternative to the wire-based systems Nexstim currently uses. The
funding provides the company with an invaluable opportunity to optimise its
system while creating momentum by taking part in the ELASTRONICS research
project.
*We adjust our target price to EUR8.40 (from EUR0.28) to account for share
consolidation*
We value Nexstim using a DCF approach using a WACC of 14%, which yields a fair
value of EUR8.40 per share. We also determined the fair value of the
diagnostics business using an EV / Sales analysis, which yields an NPV of
EUR7.0m and a valuation floor of EUR17.3m including EUR10.3m cash (June 2018).
NBT represents additional upside, bringing the total equity value to EUR27.7m.
We reiterate and maintain our OUTPERFORM recommendation and adjust our target
price to EUR8.40 (from EUR0.28) in line with the 1:30 share consolidation.
Kind regards,
Martin Piehlmeier | Analyst
goetzpartners Healthcare Research Team | Research Team
goetzpartners securities Limited
The Stanley Building, 7 Pancras Square, London, N1C 4AG, England, UK.
T +44 (0) 203 859 7725 | martin.piehlmeier@goetzpartners.com /
healthcareresearch@goetzpartners.com
www.goetzpartnerssecurities.com [1]
Registered in England No. 04684144.
Managing Directors: Dr Stephan Goetz, Martin Brunninger and Ulrich Kinzel.
*goetzpartners securities Limited - Team Members*
Equity Research Analysts - Martin Brunninger, Brigitte de Lima, Chris Redhead
and Martin Piehlmeier.
Sales / Marketing - Erland Sternby.
Corporate Finance - Ulrich Kinzel, Wolf Dornbusch and Youchen Xin.
Corporate Access and IR - Tanya Tracey and Bettina Ellinghorst.
Compliance - Paul W. Dunne.
Click here [2] to see our privacy policy.
GPSL has a formal client relationship with Nexstim OYJ.
GPSL publishes and distributes "Investment" Research and "Corporate Sponsored"
Research. Our Corporate Sponsored Research and investor meetings (e.g. NDRs, 1
to 1 meetings) are free to access and attend and is not classified as an
inducement in a post-MiFID2 world, this is because the issuer is paying GPSL.
GPSL does not offer any execution or market making services. This is a
marketing communication as defined by the Financial Conduct Authority ("FCA").
The information herein is considered to be an acceptable minor non-monetary
benefit as defined under FCA COBS 2.3A19(5).
In accordance with the General Data Protection Regulation ("GDPR [3]") - if
you would like to be removed / unsubscribed from our CRM (also please note
that you are free to contact GPSL at any time in the future to have your
e-mail subscription amended), please e-mail:
researchproduction@goetzpartners.com
About GPSL [1]: goetzpartners securities Limited is a member of the
goetzpartners group, and a leading pan European investment bank and research
company. We bring together a wide range of expertise, insights and innovations
to advance the interests of our clients around the world. The fast-changing
environment brings challenges for businesses and investors. Research
innovation, digital transformation and disruptive business ideas reshuffle the
corporate world at a relentless pace. Our sector knowledge and our global
footprint bring together corporate intelligence and a deep understanding of
the industry with a wide network of top decision makers. These collective
insights help our clients to stay at the leading edge of change.
This research report is intended for use only by persons who qualify as
professional investors or eligible counterparties (institutional investors) in
the applicable jurisdiction, and not by any private individuals or other
persons who qualify as retail clients.
This communication (including any attachments) from goetzpartners securities
Limited ("GPSL") is confidential and may contain information which is
proprietary, privileged or otherwise legally protected against unauthorised
use or disclosure. If you receive this communication in error or are not the
intended recipient of this communication, please delete and destroy all copies
in your possession, notify the sender that you have received this
communication, and note that any review or dissemination of, or the taking of
any action in reliance on this communication is expressly prohibited. GPSL
shall not be liable for the improper or incomplete transmission of the
information contained in this communication nor for any delay in its receipt
or damage to your system. GPSL does not guarantee that the integrity of this
communication has been maintained nor that this communication is free of
viruses, interceptions or interference and makes no warranties in relation to
these matters. This is not an offer or a solicitation to buy or sell
securities or investment products, or an official confirmation. GPSL record
electronic and phone communications in accordance with FCA and MiFID2
regulations, they will be monitored for regulatory and training purposes. GPSL
[4] is authorised and regulated by the Financial Conduct Authority of the
United Kingdom (Firm Reference Number: 225563).
Click on the following link for the GPSL MiFID2 Investor Guidance Notice [5]
GPSL Equity Research publications are available on the following aggregators
and via news distribution circuits (For Institutional Use Only): AlphaMetry
[6], AlphaSense, Bloomberg (GOET), Capital IQ, EQS, FACTSET, ResearchFN [7],
Research Tree [8], RNS Reach, Sentieo [9] and Thomson Reuters.
Please copy the below link and paste it into your browser for the full pdf
version of the equity research report:
https://gp.bluematrix.com/sellside/EmailDocViewer?encrypt=f8b6e0af-893a-4b04-a
825-4305b56a5fd1&mime=pdf&co=gp&id=paul.dunne@goetzpartners.com&source=library
View [10]
*Free to access research and investor meetings in a post-MiFID2 world.*
*This research report is intended for use only by persons who qualify as
professional investors or eligible counterparties (institutional investors) in
the applicable jurisdiction, and not by any private individuals or other
(MORE TO FOLLOW) Dow Jones Newswires
November 28, 2018 08:10 ET (13:10 GMT)
persons who qualify as retail clients.* Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. End of Announcement - EQS News Service 752259 28-Nov-2018 1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=750ca54579c5d5447638f7f35718f4d1&application_id=752259&site_id=vwd&application_name=news 2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=e4cf3d45df1d07e4e36e54790266d6f1&application_id=752259&site_id=vwd&application_name=news 3: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=105c239b1a4ab584252dd4cb0ab60fcc&application_id=752259&site_id=vwd&application_name=news 4: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=ba4d174d6cc17a15461e9920a97cb6e6&application_id=752259&site_id=vwd&application_name=news 5: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=78ace63222a52cf083b315624375737d&application_id=752259&site_id=vwd&application_name=news 6: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=74ec96f086effd6902b227645be3904c&application_id=752259&site_id=vwd&application_name=news 7: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=4ca72a1f25bfe4e057f55b4178d31406&application_id=752259&site_id=vwd&application_name=news 8: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=e6502ecec4e43c9ec21d32670b12b227&application_id=752259&site_id=vwd&application_name=news 9: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=e3895772493fb088c9401b3187f667a7&application_id=752259&site_id=vwd&application_name=news 10: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=9cd084d64be53cd9763554438036e186&application_id=752259&site_id=vwd&application_name=news
(END) Dow Jones Newswires
November 28, 2018 08:10 ET (13:10 GMT)
